Overview

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Status:
Completed

Trial end date:
2019-11-12

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral risperidone, or another OAP]) in delaying time to treatment failure. The study will also evaluate changes in cognition, functioning, brain intracortical myelin (ICM) volume following treatment with PP compared with OAP in participants with recent-onset schizophrenia or schizophreniform disorder.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Scientific Affairs, LLC

Treatments:

Antipsychotic Agents
Aripiprazole
Haloperidol
Haloperidol decanoate
Olanzapine
Paliperidone Palmitate
Perphenazine
Polystyrene sulfonic acid
Quetiapine Fumarate
Risperidone